Search markets, companies, evidence, and pages
CIK 72331 · Diversified Industrial Compounders
N/A
Market data as of N/A
Financials: LTM / latest available company filings
Sources: FMP, NDSN filings, SEC EDGAR
$15,816
Market cap ($MM)
$17,837
Enterprise value ($MM)
$2,846
Revenue · LTM ($MM)
$914
EBITDA · LTM ($MM)
32%
EBITDA margin
6.3x
EV / revenue
19.5x
EV / EBITDA
2.0x
Net debt / EBITDA
Coverage
The analytical read on the name and the balance-sheet capacity behind the program.
Key points
Balance sheet & capacity
Indicative capacity read: 2.0x net debt / EBITDA with EBITDA of $914MM.
$120
Cash & equiv. ($MM)
$1,984
Total debt ($MM)
$1,864
Net debt ($MM)
2.0x
Net debt / EBITDA
Valuation
NDSN versus the scaled public Diversified Industrial Compounders comparables.
Indexed share-price performance
NDSN versus available Diversified Industrial Compounders peers and SPY.
+30%
NDSN
N/A
Peer med.
+79%
SPY
Indexed to 100 from May 28, 2021 through May 26, 2026. Source: FMP month-end close history.
| Company | Ticker | Revenue ($MM) | EBITDA ($MM) | Margin | Market cap ($MM) | EV ($MM) | EV / rev | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| Nordson Corporation | NDSN | $2,846 | $914 | 32% | $15,816 | $17,837 | 6.3x | 19.5x | 2.0x |
Financials via Financial Modeling Prep (SEC-derived TTM). EV/EBITDA distribution: each dot a live peer, band = interquartile range, line = median. Impossible values (EBITDA > revenue, negative-EBITDA multiples) shown NM.
M&A program
NDSN's disclosed acquisition footprint and the deals behind it.
Disclosed acquisitions
102
Active years
17
Named deals
2
Avg / active year
6.0
Acq. cash outflow ($MM)
N/A
Banker read
Annual acquisitions + disclosed spend
NDSN count bars show acquisition cadence; the spend line shows when the program required larger capital deployment.
Program diagnostics
Recent / prior
2 / 5
Last three years is down 60% vs prior three.
Peak count year
FY17
4 disclosed acquisitions in the peak visible year.
Recent spend
$3.0B
is up 820% vs prior three; peak FY23 at $1.4B.
Named evidence
2 rows
2.0% selected source-cited transaction coverage.
Selected transactions
| Date | Target | Segment | Consideration ($MM) | Strategic rationale | Source |
|---|---|---|---|---|---|
| Mar 31, 2017 | Vention Medical’s Advanced Technologies business | Diversified industrial compounders | $705 | On March 31, 2017, we completed the acquisition of Vention Medical’s Advanced Technologies business (“Vention”), a Salem, New Hampshire leading designer, developer and manufactu... | 10-K† |
| Dec 14, 2006 | Dage Holdings Limited | Diversified industrial compounders | $230 | On December 14, 2006, the Company announced that it had acquired Dage Holdings Limited, a leading manufacturer of testing and inspection equipment used in the semiconductor and... | 10-K† |
Acquisitions disclosed/extracted from SEC filings; not necessarily full M&A history. Disclosed acquisition cash outflow is cumulative "payments for acquisitions, net of cash acquired" from the 10-K cash-flow statements (a cash outflow, not deal value). Built on 4 SEC-backed facts across 2 cited filings.
Evidence
A collapsed investigation trail for the SEC filings behind the financials, annual M&A cadence, named transactions, and management language.
Annual 10-Ks
17
Named deal filings
2
Recent SEC filings
0
Evidence clips
2
| Fiscal year | Filing date | Form | Status | Count | Cash spend | Purchase consideration | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 17, 2025 | Annual M&A 10-K | accepted | N/A | N/A | N/A | SEC filing |
| FY2024 | Dec 18, 2024 | Annual M&A 10-K | accepted | 1 | $790MM | $790MM | SEC filing |
| FY2023 | Dec 20, 2023 | Annual M&A 10-K | quarantined (2 issue) | 1 | $1,423B | $1,423B | SEC filing |
| FY2019 | Dec 13, 2019 | Annual M&A 10-K | warning (1 warn) | 1 | $12.5MM | N/A | SEC filing |
| FY2017 | Dec 15, 2017 | Annual M&A 10-K | accepted | 4 | N/A | $90.7MM | SEC filing |
| FY2016 | Dec 15, 2016 | Annual M&A 10-K | accepted | 1 | $42.7MM | $42.7MM | SEC filing |
| FY2015 | Dec 15, 2015 | Annual M&A 10-K | quarantined (1 warn, 1 issue) | 3 | N/A | $76B | SEC filing |
| FY2014 | Dec 15, 2014 | Annual M&A 10-K | accepted | 2 | $187MM | $186MM | SEC filing |
| FY2012 | Dec 17, 2012 | Annual M&A 10-K | accepted | 3 | N/A | $444MM | SEC filing |
| FY2011 | Dec 16, 2011 | Annual M&A 10-K | accepted | 3 | $293MM | $348MM | SEC filing |
| FY2010 | Dec 17, 2010 | Annual M&A 10-K | accepted | 1 | $18.6MM | $22.0MM | SEC filing |
| FY2009 | Dec 18, 2009 | Annual M&A 10-K | accepted | N/A | N/A | N/A | SEC filing |
| FY2007 | Dec 21, 2007 | Annual M&A 10-K | accepted | 3 | $98B | $330B | SEC filing |
| FY2006 | Jan 12, 2007 | Annual M&A 10-K | accepted | 1 | N/A | N/A | SEC filing |
| FY2005 | Jan 13, 2006 | Annual M&A 10-K | accepted | 1 | $0.6MM | $0.6MM | SEC filing |
| FY2004 | Jan 14, 2005 | Annual M&A 10-K | accepted | 1 | $4.0MM | $4.5MM | SEC filing |
| FY2003 | Jan 21, 2004 | Annual M&A 10-K | warning (1 warn) | 1 | $0.5MM | N/A | SEC filing |
| Filing date | Form | Targets / topics | Support | Source |
|---|---|---|---|---|
| Dec 15, 2017 | 10-K | Vention Medical’s Advanced Technologies business | Annual M&ANamed deals | SEC filing |
| Jan 12, 2007 | 10-K | Dage Holdings Limited | Annual M&ANamed deals | SEC filing |
Vention Medical’s Advanced Technologies business
10-K - Dec 15, 2017
On March 31, 2017, we completed the acquisition of Vention Medical’s Advanced Technologies business (“Vention”), a Salem, New Hampshire leading designer, developer and manufacturer of minimally inv...
Dage Holdings Limited
10-K - Jan 12, 2007
On December 14, 2006, the Company announced that it had acquired Dage Holdings Limited, a leading manufacturer of testing and inspection equipment used in the semiconductor and printed circuit boar...
Annual M&A counts and disclosed spend are extracted from SEC acquisition disclosures and cash-flow statements; named-deal rows carry direct filing links where the filing identifies the target or consideration.